Aclaris Therapeutics Announces Leadership Transition
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company, has announced a significant leadership transition in its scientific team. Roland Kolbeck, Ph.D. has been appointed as the new Chief Scientific Officer, succeeding Joe Monahan, Ph.D., who will transition to a Special Scientific Advisor role through Q1 2026 as part of his planned retirement.
Dr. Kolbeck brings nearly 30 years of senior R&D leadership experience, most recently serving as CSO at Spirovant Sciences. His notable achievements include his role as VP and Head of Respiratory, Inflammation and Autoimmune Research at MedImmune, where six monoclonal antibodies from his portfolio received FDA approval. The transition comes as Aclaris continues to develop its portfolio of immuno-inflammatory product candidates, including next-generation kinase inhibitors and first-in-class bispecific antibodies.
Aclaris Therapeutics (NASDAQ: ACRS), un'azienda biofarmaceutica in fase clinica, ha annunciato un importante cambiamento nella sua squadra scientifica. Roland Kolbeck, Ph.D. 猫 stato nominato nuovo Chief Scientific Officer, succedendo a Joe Monahan, Ph.D., che assumer脿 il ruolo di Consulente Scientifico Speciale fino al primo trimestre del 2026, nell'ambito del suo pensionamento programmato.
Il dottor Kolbeck vanta quasi 30 anni di esperienza nella leadership R&D senior, avendo ricoperto recentemente il ruolo di CSO presso Spirovant Sciences. Tra i suoi successi pi霉 rilevanti vi 猫 la posizione di VP e Responsabile della Ricerca su Malattie Respiratorie, Infiammazioni e Autoimmuni presso MedImmune, dove sei anticorpi monoclonali del suo portafoglio hanno ottenuto l'approvazione FDA. Questa transizione avviene mentre Aclaris continua a sviluppare il suo portafoglio di candidati farmaci immuno-infiammatori, inclusi inibitori di chinasi di nuova generazione e anticorpi bispecifici di prima classe.
Aclaris Therapeutics (NASDAQ: ACRS), una compa帽铆a biofarmac茅utica en etapa cl铆nica, ha anunciado una importante transici贸n en su equipo cient铆fico. Roland Kolbeck, Ph.D. ha sido nombrado nuevo Director Cient铆fico, reemplazando a Joe Monahan, Ph.D., quien asumir谩 el rol de Asesor Cient铆fico Especial hasta el primer trimestre de 2026 como parte de su jubilaci贸n planificada.
El Dr. Kolbeck aporta casi 30 a帽os de experiencia en liderazgo senior de I+D, habiendo sido recientemente CSO en Spirovant Sciences. Entre sus logros destacados est谩 su cargo como vicepresidente y jefe de investigaci贸n en Respiratorio, Inflamaci贸n y Enfermedades Autoinmunes en MedImmune, donde seis anticuerpos monoclonales de su cartera recibieron aprobaci贸n de la FDA. Esta transici贸n ocurre mientras Aclaris contin煤a desarrollando su cartera de candidatos a productos inmuno-inflamatorios, incluidos inhibidores de quinasas de nueva generaci贸n y anticuerpos bispec铆ficos de primera clase.
Aclaris Therapeutics (NASDAQ: ACRS)電� 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 瓿柬暀 韺�鞚� 欷戨寑頃� 毽崝鞁� 氤�頇旊ゼ 氚滍憸頄堨姷雼堧嫟. 搿る灉霌� 旖滊病 氚曥偓臧� 靸堧鞖� 斓滉碃 瓿柬暀 毂呾瀯鞛�(CSO)搿� 鞛勲獏霅橃棃鞙茧┌, 臁� 氇倶頃� 氚曥偓電� 瓿勴殟霅� 鞚�韲挫棎 霐半澕 2026雲� 1攵勱赴旯岇 韸闺硠 瓿柬暀 瓿犽 鞐暊搿� 鞝勴櫂頃� 鞓堨爼鞛呺媹雼�.
旖滊病 氚曥偓電� 瓯办潣 30雲勱皠鞚� 瓿犾渼 鞐瓣惮臧滊皽 毽崝鞁� 瓴巾棙鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 斓滉芳鞐愲姅 Spirovant Sciences鞚� CSO搿� 攴茧頄堨姷雼堧嫟. 攴胳潣 欤检殧 靹标臣搿滊姅 MedImmune鞐愳劀 順疙潯旮�, 鞐检 氚� 鞛愱皜氅挫棴 鞐瓣惮 攵�氍� 攵�靷灔 瓴� 毂呾瀯鞛愲靹� 鞐劘 臧滌潣 雼伌搿� 頃泊臧� FDA 鞀轨澑鞚� 氚涭潃 鞝愳澊 鞛堨姷雼堧嫟. 鞚措矆 毽崝鞁� 鞝勴櫂鞚� Aclaris臧� 彀劯雽� 韨る倶鞝� 鞏奠牅鞝� 氚� 斓滌磮鞚� 鞚挫韸轨澊靹� 頃泊毳� 韽暔頃� 氅挫棴鞐检 鞝滍拡 頉勲炒甑� 臧滊皽鞚� 瓿勳啀頃橂姅 臧�鞖措嵃 鞚措（鞏挫鞀惦媹雼�.
Aclaris Therapeutics (NASDAQ : ACRS), une soci茅t茅 biopharmaceutique en phase clinique, a annonc茅 une transition importante au sein de son 茅quipe scientifique. Roland Kolbeck, Ph.D. a 茅t茅 nomm茅 nouveau Chief Scientific Officer, succ茅dant 脿 Joe Monahan, Ph.D., qui assumera un r么le de conseiller scientifique sp茅cial jusqu'au premier trimestre 2026 dans le cadre de sa retraite planifi茅e.
Le Dr Kolbeck apporte pr猫s de 30 ans d'exp茅rience en direction R&D senior, ayant r茅cemment occup茅 le poste de CSO chez Spirovant Sciences. Parmi ses r茅alisations notables figure son r么le de vice-pr茅sident et responsable de la recherche en maladies respiratoires, inflammation et auto-immunit茅 chez MedImmune, o霉 six anticorps monoclonaux de son portefeuille ont re莽u l'approbation de la FDA. Cette transition intervient alors qu'Aclaris poursuit le d茅veloppement de son portefeuille de candidats produits immuno-inflammatoires, incluant des inhibiteurs de kinase de nouvelle g茅n茅ration et des anticorps bisp茅cifiques de premi猫re classe.
Aclaris Therapeutics (NASDAQ: ACRS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat eine bedeutende F眉hrungs盲nderung in seinem wissenschaftlichen Team bekannt gegeben. Roland Kolbeck, Ph.D. wurde zum neuen Chief Scientific Officer ernannt und tritt die Nachfolge von Joe Monahan, Ph.D. an, der im Rahmen seines geplanten Ruhestands bis zum ersten Quartal 2026 als Special Scientific Advisor t盲tig sein wird.
Dr. Kolbeck verf眉gt 眉ber fast 30 Jahre Erfahrung in leitenden Positionen im Bereich Forschung und Entwicklung und war zuletzt CSO bei Spirovant Sciences. Zu seinen bemerkenswerten Erfolgen z盲hlt seine T盲tigkeit als Vizepr盲sident und Leiter der Forschung f眉r Atemwegserkrankungen, Entz眉ndungen und Autoimmunerkrankungen bei MedImmune, wo sechs monoklonale Antik枚rper aus seinem Portfolio die FDA-Zulassung erhielten. Der F眉hrungswechsel erfolgt, w盲hrend Aclaris weiterhin sein Portfolio an immun-entz眉ndlichen Produktkandidaten entwickelt, darunter Kinaseinhibitoren der n盲chsten Generation und erstmalige bispezifische Antik枚rper.
- None.
- Loss of long-term scientific leader as Dr. Monahan moves toward retirement
- Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer -
- Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned Retirement -
WAYNE, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Roland Kolbeck, Ph.D. has been appointed as Chief Scientific Officer, replacing Joe Monahan, Ph.D. who will remain with the Company as Special Scientific Advisor to the Chief Executive Officer through the first quarter of 2026 as part of his planned retirement. Dr. Kolbeck鈥檚 extensive experience in areas including inflammation and antibody development will be important as the Company develops its growing portfolio of immuno-inflammatory product candidates, including its next generation kinase and cytokine signaling pathway inhibitors and potential first-in-class bispecific antibodies.
鈥淥n behalf of the executive team, I鈥檓 glad to welcome Roland to Aclaris as our incoming Chief Scientific Officer,鈥� said Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris. 鈥淗is reputation as an inspirational scientific leader is unmatched, as is his expertise stemming from his time leading Respiratory, Inflammation and Autoimmune (RIA) research at MedImmune. This expertise will be important to the Company as we progress.鈥�
Dr. Walker continued, 鈥淚 also thank Joe for his steady leadership and dedication to scientific excellence. He has been central to Aclaris鈥� resilience and evolution, including successfully building a renowned discovery team in St. Louis that we expect to continue to fuel the Company鈥檚 pipeline. Joe will remain heavily involved with Aclaris as a scientific advisor during this transitional period as he moves toward retirement in 2026.鈥�
鈥淯nder Joe鈥檚 leadership, Aclaris has developed world-class expertise in kinase small molecule discovery, including a proprietary development platform that is expected to deliver new INDs starting as soon as next year,鈥� said Dr. Kolbeck. 鈥淭he Company has a growing pipeline of small and large molecules and the experience to lead therapeutic innovation in I&I 鈥� along with the cash reserves needed to accomplish its goals. This is a great time to join the Aclaris team, and I look forward to contributing to the Company鈥檚 continued success.鈥�
Roland Kolbeck, Ph.D., brings nearly three decades of senior R&D leadership in small and large biopharmaceutical companies and a proven track record of successful drug development to Aclaris. He joins the team from Spirovant Sciences, where he served as Chief Scientific Officer and directed the company鈥檚 strategy related to new indications, targets, and investments. Previously, Dr. Kolbeck was Vice President, Head of Respiratory, Inflammation and Autoimmune Research (RIA) at MedImmune, AstraZeneca鈥檚 global biologics organization, where he provided strategic direction as Chair of the RIA Research Committee and as a member of the Research Leadership Team and Early-Stage Portfolio Committee. Six monoclonal antibodies originating from the RIA portfolio have since been approved by the FDA. Prior to Medimmune, he served in senior scientific roles at Peptimmune and Millennium Pharmaceuticals. Dr. Kolbeck has published over 100 peer-reviewed articles in scientific journals such as Nature, Immunity and New England Journal of Medicine. He earned his M.S. and Ph.D. at the University of Regensburg and Max Planck Institute for Neurobiology (now the Max Planck Institute for Biological Intelligence), in Munich, Germany.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on (formerly Twitter) at @AclarisTx and on .
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥渨ill,鈥� and similar expressions, and are based on Aclaris鈥� current beliefs and expectations. These forward-looking statements include expectations regarding the Company鈥檚 pipeline, including that the discovery platform will expand the Company鈥檚 pipeline, the potential to have first-in-class bispecific antibodies, that new INDs will be filed in 2026, that the Company has the cash reserves it needs to accomplish its goals, and regarding the future contributions of Dr. Kolbeck. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris鈥� reliance on third parties over which it may not always have full control, Aclaris鈥� ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris鈥� Annual Report on Form 10-K for the year ended December 31, 2024, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the 鈥淪EC Filings鈥� page of the 鈥淚nvestors鈥� section of Aclaris鈥� website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
FAQ
Who is the new Chief Scientific Officer of Aclaris Therapeutics (NASDAQ: ACRS)?
What is happening to Aclaris Therapeutics' previous CSO Joe Monahan?
What is Roland Kolbeck's background before joining Aclaris (ACRS)?
What types of drugs is Aclaris Therapeutics (ACRS) developing?
When will Aclaris Therapeutics (ACRS) expect new IND submissions?
